Buy CJC-1295 (no DAC) + Ipamorelin in Australia
CJC-1295 (no DAC) + Ipamorelin can be ordered in Australia from Australian Research Peptides, two peptides freeze-dried together into a single 10 mg vial that works one gland from two directions. The 29-amino-acid CJC-1295 half copies growth-hormone-releasing hormone and triggers its receptor; the five-amino-acid ipamorelin half switches on the ghrelin receptor next to it. Both routes push the pituitary to put out growth hormone, and drying the pair together fixes the ratio and leaves one vial to prepare. ARP ships to every state and territory. For in vitro research purposes only.
Growth Hormone Research · Lyophilised Powder · Batch-tested · SKU ARP-CJCIPA-10
$124.99
1
2+ vials: 5% off — applied automatically in the cart
Presentation
10 mg per vial
Grade
High-Purity Research Grade
Form
Lyophilised Powder
Category
Growth Hormone Research
Same-day dispatch on business-day orders placed before 12pm AEST, Mon–Fri
Tracked shipping Australia-wide ·typically 1–2 business days to most areas by Express Post · free post over $199, free Express over $299
Batch certificates — published in the COA library
For in vitro research purposes only. Not for human consumption. Not for animal consumption. This product is not a drug, food, cosmetic, or dietary supplement. Any amounts shown are reported from published studies, with the species or trial population named. ARP gives no dosing, medical or therapeutic guidance of its own.
CJC-1295 (no DAC) + Ipamorelin · 10 mg
$124.99
Frequently Bought Together
About CJC-1295 (no DAC) + Ipamorelin
This vial holds two peptides that act on the pituitary through different receptors. CJC-1295 without DAC is an analogue of growth-hormone-releasing hormone, the hypothalamic signal carried to the anterior pituitary that drives pulsed growth hormone release. Ipamorelin binds a separate target. Raun and colleagues, working with rat pituitary cells and with conscious pigs, described it as an agonist at the ghrelin receptor, formally named the growth hormone secretagogue receptor. An agonist is a molecule that switches a receptor on.
Australian Research Peptides supplies the no-DAC form, and the distinction matters. CJC-1295 exists in two versions that are routinely confused. The DAC version carries an added Drug Affinity Complex, a lysine linked through maleimidopropionic acid, which binds serum albumin and stretches the peptide's half-life into days. The no-DAC version has no such tail, and it is the same compound catalogued elsewhere as Modified GRF (1-29). Both peptides dry together into one powder, so the strength shown covers the pair rather than either one alone.
Australian Research Peptides supplies the pair as a single freeze-dried solid, white to off-white, sealed in a tamper-evident glass vial. Nothing separates the two peptides once they are in that glass, which is why a reconstitution volume sets concentration and can never set ratio. The material is a laboratory reference compound, characterised for work in glassware and cell culture rather than for any use in a living subject.
What is in the vial
| Component | Amount per vial |
|---|---|
| CJC-1295 (no DAC) — no DAC — not the DAC-modified analogue; also catalogued as Modified GRF (1-29) | ~5 mg |
| Ipamorelin | ~5 mg |
| Total | 10 mg per vial |
Content reviewed
Further reading: Peptide Types, Categories and Blends · CJC-1295 With DAC vs No DAC: What Is the Difference?
CJC-1295 (no DAC) + Ipamorelin specifications, storage and shipping
- Compound: CJC-1295 (no DAC) + Ipamorelin
- Also known as: CJC-1295 without DAC (Modified GRF (1-29)) with ipamorelin
- Class: Two-peptide blend: a growth-hormone-releasing-hormone analogue with a growth-hormone secretagogue-receptor ligand
- Appearance: White to off-white lyophilised powder
- Sizes & SKUs: 10 mg (ARP-CJCIPA-10)
- Presentation: sealed glass vial
- Form: Lyophilised Powder
- Grade: High-purity research grade
- Purity verification: HPLC-assayed on every batch to a minimum of 99% purity — the measured result for your batch is stated on its Certificate of Analysis
- Identity confirmation: Mass spectrometry
- Batch traceability: every batch is tested, with its certificate published in the COA library
- Classification: In vitro research purposes only — laboratory reference material
- Lyophilised — long term
- −20 °C to −80 °C — long-term storage
- Lyophilised — short term
- 2–8 °C — refrigerated, for a few months
- Reconstituted
- 2–8 °C — use within 8–12 weeks
Every batch undergoes HPLC purity analysis and mass-spectrometry identity confirmation. The full laboratory report is published in the COA library.
Business-day orders before 12pm AEST are dispatched the same day with tracked, discreet shipping. Standard delivery within Australia typically takes 2–5 business days. See Shipping & Delivery for details, and follow your parcel on the Track Order page.
For in vitro research purposes only. Not for human consumption. Not for animal consumption. Not a drug, food, cosmetic, or dietary supplement. No therapeutic or medical claims are made.
Questions about CJC-1295 (no DAC) + Ipamorelin
This question guide from Australian Research Peptides covers CJC-1295 (no DAC) + Ipamorelin in Australia: what the listing contains, live buying and delivery questions, research context, handling, testing and comparisons. Start with the quick answers, then open the topic group that matches your search.
Buying, price and availability
Australian Research Peptides supplies CJC-1295 (no DAC) + Ipamorelin within Australia. Orders can be paid by PayID or bank transfer. Anything confirmed before 12pm AEST, Monday to Friday, is dispatched that afternoon. The vial holds the no-DAC form rather than the DAC-modified peptide of nearly the same name, under code CJCIPA.
Australian Research Peptides Pty Ltd is the company behind CJC-1295 (no DAC) + Ipamorelin, trading as ARP and posting to every state and territory, Tasmania and the Northern Territory included, by Express or tracked services. The blend sits in Growth Hormone Research beside tesamorelin and standalone ipamorelin, and is the only two-peptide entry of the three.
One price covers CJC-1295 (no DAC) + Ipamorelin, because Australian Research Peptides carries the blend at one strength only rather than a ladder of sizes. Each vial is quoted in Australian dollars, the figure taken live from its catalogue record. Peptide-graded lines earn an automatic multi-vial discount on repeat vials, and this blend qualifies. A vial of it and a vial of standalone ipamorelin count as separate lines.
CJC-1295 (no DAC) + Ipamorelin is sold by Australian Research Peptides through its online catalogue alone, with no orders taken by telephone and none by email. Both payment routes are bank-based — PayID, or a straight transfer — and no card, digital wallet or crypto payment is accepted for anything in the range. Stock is held and posted within Australia. When the blend is unavailable, an email alert can be registered against it.
Australian Research Peptides carries CJC-1295 with Ipamorelin; Chemist Warehouse does not, and no Australian pharmacy does. Growth-hormone secretagogues of this kind hold no Australian registration, so there is no product for a pharmacist to hand over and no prescription that could be written for one. ARP catalogues the pair as a single 10 mg research vial under Growth Hormone Research.
Identity, names and exact format
CJC-1295 (no DAC) + Ipamorelin is a two-peptide blend in one vial: a growth-hormone-releasing hormone analogue paired with a growth hormone secretagogue. The two act on the pituitary through different receptors, which is the reason they are studied as a pair. The no DAC part matters — this is the short-acting form, not the DAC-modified analogue that carries a much longer duration.
CJC-1295 (no DAC) + Ipamorelin holds two chains of very different length. The CJC-1295 half runs 29 amino acids, matching the first 29 of growth-hormone-releasing hormone with four positions swapped. Ipamorelin runs five, and two of its five are mirror-image D-forms that a plain sequence readout cannot tell from ordinary ones. Both chains dry into one powder rather than staying separate.
A CJC-1295 (no DAC) + Ipamorelin vial from Australian Research Peptides holds 10 mg in total, blended at the standard 1:1 ratio, so it is about 5 mg of each peptide. The two dry into one cake, which is why the strength on the label is the total for the pair rather than the amount of either one. Those are nominal formulation figures. Blend labels are genuinely ambiguous across the industry, because the same number can mean a combined total or that amount of each peptide. When an exact-strength batch document is published, its laboratory-measured amount for each chain takes precedence over the nominal formulation figures.
CJC-1295 (no DAC) + Ipamorelin has no single scientific synonym because it contains two peptides. CJC-1295 without DAC is also catalogued as Modified GRF (1-29), often shortened to Mod GRF 1-29, while Ipamorelin carries the development code NNC 26-0161. Australian Research Peptides uses CJCIPA as the catalogue code for this specific two-peptide vial.
Australian Research Peptides supplies this CJC-1295 listing in the no-DAC form, also catalogued as Modified GRF (1-29). The DAC version carries an extra lysine bearing a Drug Affinity Complex, which binds serum albumin and keeps the peptide circulating far longer. That makes it a structurally different molecule, and it is not listed here. Contact Australian Research Peptides support if the DAC form is what the work needs.
One — both peptides are freeze-dried together into a single powder inside one sealed, tamper-evident glass vial. This is not two vials boxed as a pair, and the two cannot be separated once dried. Anyone needing them apart can use Australian Research Peptides' standalone ipamorelin listing, which supplies that compound on its own.
Research context and evidence
CJC-1295 (no DAC) + Ipamorelin pairs two peptides that act at two different receptors on one gland. The CJC-1295 half copies growth-hormone-releasing hormone closely enough to switch on its receptor, which sits on somatotroph cells in the anterior pituitary. Ipamorelin binds the growth hormone secretagogue receptor instead, the one ghrelin normally uses. Raun and colleagues measured that in rat pituitary cells and in conscious swine, not in people.
No published trial tests this exact pairing. Separate work exists on each half. Raun and colleagues found ipamorelin released growth hormone in rats and swine without raising ACTH or cortisol, even at over 200 times the half-maximal dose. Bowers and colleagues found a different releasing peptide, given with GHRH, released more growth hormone in 18 healthy men than either alone.
Raun and colleagues put ipamorelin's half-maximal dose at 2.3 nmol/kg in conscious swine and 80 nmol/kg in anaesthetised rats. Alba and colleagues gave 2 micrograms of CJC-1295 per injection to GHRH-knockout mice, from one week old, for five weeks. That mouse work used the DAC form, not the no-DAC form in this listing. These are study parameters, not amounts for anything else.
CJC-1295 (no DAC) + Ipamorelin runs on two clocks, and only one has ever been timed. Ipamorelin's terminal half-life ran about two hours in Gobburu's 1999 human study. Its partner is a modified GRF(1-29) carrying no published figure of its own; the unmodified parent showed an elimination phase near ten minutes in Rafferty's 1985 rat work, and those substitutions exist precisely to slow that down. Teichman's 2006 DAC version, lasting days, is a separate molecule.
Growth-hormone release after a GHRH analogue and a secretagogue is measured in minutes to hours in the published pharmacology, because that is what the assays sampled. Downstream changes are a different question, and no controlled human trial of this specific blend has been published, so there is no evidenced timeline for anything beyond the hormone response itself.
Discontinuation of the CJC-1295 (no DAC) + Ipamorelin pairing has never been investigated. Neither compound finished development, no trial ran the two together, and the published record tracks nobody once administration ceased. Both work by prompting the body's own growth-hormone release rather than supplying a hormone, which is why suppression arguments borrowed from anabolic drugs do not carry over — though that reasoning is theory, and theory is not data.
Two compounds with no controlled human trial between them do not add up to a known profile. The blend has never been tested in a published human study, so nothing about its tolerability has been measured. Ipamorelin's selectivity finding is about receptor targeting in early research and is not a safety result.
CJC-1295 (no DAC) + Ipamorelin has no published trial of its own, so nothing has measured this exact pairing. The supporting work sits one molecule away: Raun and colleagues found ipamorelin released growth hormone in rats and swine without raising ACTH or cortisol, and Bowers and colleagues found a different secretagogue given alongside a GHRH analogue released more growth hormone in 18 healthy men than either did by itself. That is a mechanism with real support, demonstrated on neighbouring compounds rather than on this blend.
Handling, storage and measurements
No — a sealed vial of this blend is dry lyophilised powder and travels and sits at ambient temperature without harm, which is why it posts with no cold pack. The fridge becomes necessary once water goes in. Dry and reconstituted are two different products as far as storage is concerned, with very different lifespans.
Nothing has gone missing: both chains dry together as one deposit totalling ten milligrams, and spread across the floor of a glass container that amounts to a faint whitish bloom. Ipamorelin runs to five amino acids and its CJC-1295 partner to twenty-nine, yet neither contributes visible volume at these weights. A sealed, tamper-evident closure is better evidence of what is inside than anything the eye picks up.
Store CJC-1295 (no DAC) + Ipamorelin frozen in its sealed vial, dry and away from light. Its CJC-1295 chain carries leucine at position 27, where growth-hormone-releasing hormone carries methionine. Peptide handling guides flag methionine as a residue that shortens shelf life. Bachem advises keeping freeze-dried peptides below minus 15 degrees, and warming a vial in a desiccator before opening it. Refrigerate the solution once made, and use it promptly.
Reconstituting CJC-1295 (no DAC) + Ipamorelin takes one preparation, because both peptides in the vial go into the same liquid. Add bacteriostatic water slowly, letting it run down the inside wall of the glass rather than landing on the powder. Swirl gently until the solid clears. Never shake. Keep the finished solution cold. The volume added sets the concentration, and Australian Research Peptides publishes worked examples for the 10 mg vial.
A CJC-1295 (no DAC) + Ipamorelin vial holds 10 mg of peptide in total. Share that mass across the water you add and you have the strength. So 1 mL gives 10 mg/mL, 2 mL gives 5 mg/mL, and 3 mL gives about 3.3 mg/mL. Those figures cover both peptides together; the even 1:1 formulation is nominal, so treat it as the recipe rather than as a measured amount for either chain. Australian Research Peptides' reconstitution calculator guide handles any other volume.
A reconstituted CJC-1295 (no DAC) + Ipamorelin vial goes to 2–8 °C and is allowed 8 to 12 weeks there by Australian Research Peptides' stated condition. Its CJC-1295 chain swaps four positions against growth-hormone-releasing hormone, and one swap exchanged the asparagine at position 8 for a glutamine — Bachem's shelf-life list names both, so that trade removed nothing.
The vial holds 10 mg in total across both peptides, so the water you add fixes the combined concentration while the ratio between the two stays exactly as it was blended. Two millilitres gives 5 mg per mL of total peptide; one gives 10 mg per mL. What the volume cannot do is separate the two compounds — that is decided in the vial, not at the bench.
CJC-1295 (no DAC) + Ipamorelin holds two peptides that take up water at their own speeds, and the interval while the slower of them is still clearing can look like a fault. Microbubbles from swirling make it more pronounced. Several minutes at room temperature resolves both. What is genuinely abnormal is a preparation staying translucent rather than turning clear, or one throwing particles once left alone.
Yes — this blend arrives dry, and bacteriostatic water is the usual diluent for taking both peptides into solution. A diluent is whatever liquid dissolves a freeze-dried powder. Bacteriostatic water is sterile water preserved with benzyl alcohol, which the DailyMed FDA label puts most commonly at 0.9 per cent, and that preservative is what lets a vial be entered more than once. Australian Research Peptides lists it separately under lab supplies, so it does not come with this one.
Ten milligrams on a CJC-1295 (no DAC) + Ipamorelin vial is the combined weight of the two peptides together, not ten of each — a distinction worth making before working anything out. At 200 mcg of blend per draw the vial gives fifty; at 300 mcg roughly thirty-three. The pair is formulated evenly at about 5 mg each, but that is a nominal figure rather than an assayed one, so anyone whose work depends on the exact split should raise it before ordering.
Testing and batch documents
Yes, Australian Research Peptides tests every batch of CJC-1295 (no DAC) + Ipamorelin before supplying it. HPLC measures purity. Mass spectrometry then checks the measured mass against two expected values, one for each peptide. That identity step earns its keep on this pairing, because it separates the no-DAC compound from the DAC-modified one sharing most of the name. Neither test reports the split between the two peptides, and neither covers sterility or endotoxin.
The certificate for the batch that vial came from, not a general document for the listing. Australian Research Peptides publishes the certificates it holds in its COA library, searchable by product name and stock code. Send us your order reference and we will match the certificate to what you were sent.
Ordering, payment and Australian delivery
A pair of these blend vials clears the Standard tracked post threshold comfortably, while a single vial falls well short of free post. The Express Post waiver is a separate and higher bar that two vials do not reach. What the threshold reads is your subtotal before the automatic multi-vial discount — qualification first, discount afterwards, so one never cancels the other.
Delivery of CJC-1295 (no DAC) + Ipamorelin runs 2–5 business days by standard tracked post and 1–2 by Express Post to much of the country, with weekends and public holidays the thing that moves that date. Australian Research Peptides packs on business days only, so an order confirmed on a Saturday goes out Monday. Carriers may still move a parcel already lodged across a weekend.
Non-instant bank transfers batch on business days, which is why the window on a CJC-1295 (no DAC) + Ipamorelin order is counted in business days and pauses over weekends. A Friday-evening transfer that lands Monday is not late. Without that rule, a weekend order could expire before any bank had a chance to move the money.
The 10 mL bacteriostatic water vial is a false economy for a single CJC-1295 (no DAC) + Ipamorelin vial. Once a water vial is first pierced it has a working life of about a month regardless of how full it is, so buying 10 mL to use 1 mL means discarding most of it. The 3 mL is the match.
Access, approval and sport questions
Australian Research Peptides supplies CJC-1295 (no DAC) + Ipamorelin for in vitro research purposes only, and never as a medicine. It is sold for in vitro work, and ARP makes no claim that it is registered or approved for use in people or animals. Buying research material and administering it to a person are separate acts under Australian law. Anyone unsure where their intended work sits should take their own regulatory advice.
No authority has licensed either component of the CJC-1295 (no DAC) + Ipamorelin blend, so the pairing has no American approval and none elsewhere. Ipamorelin's development halted after Phase 2, and CJC-1295 never reached a marketed product either. Tesamorelin is the rare growth-hormone-axis peptide that did win approval; neither of these two did. Both are supplied as unregistered material with no label behind them.
CJC-1295 (no DAC) + Ipamorelin is banned in sport twice over. CJC-1295 is named among the GHRH analogues in section S2.2, and ipamorelin among the growth hormone secretagogues in that same section, so one vial carries two separate breaches. Nothing about it is permitted out of season. Anti-doping enforcement in Australia rests with Sport Integrity Australia.
Neither peptide in this blend is registered as a medicine anywhere in the world, so there is no approved foreign product to bring in under a personal-importation exemption — the scheme assumes something a regulator somewhere has licensed. The TGA controls what unapproved goods may enter and Border Force applies that at the frontier. An order placed with Australian Research Peptides never raises it, because the vial is posted domestically.